A. Banu

Matched case‐control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel‐induced onycholysis and cutaneous toxicity of the foot

S. Oudard, F. Scotté, E. Levy, 2008, Cancer.

What is the real impact of bone pain on survival in patients with metastatic hormone‐refractory prostate cancer treated with docetaxel?

Eric Levy, Gabriel Kacso, S. Oudard, 2009, BJU international.

Docetaxel versus mitoxantrone as first-line chemotherapy for hormone-refractory prostate cancer (HRPC) patients. A meta-analysis of 3-year overall survival results

S. Oudard, F. Scotté, E. Levy, 2005 .

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.

M. Poupon, S. Oudard, F. Scotté, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meta-Analysis of Randomised Trials Comparing Gemcitabine-Based Doublets versus Gemcitabine Alone in Patients with Advanced and Metastatic Pancreatic Cancer

G. Chatellier, P. Rougier, S. Oudard, 2007, Drugs & aging.

Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.

S. Culine, B. Duclos, B. Escudier, 2007, The Journal of urology.

Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy.

S. Oudard, F. Scotté, A. Fischer, 2009, European urology.

Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients.

F. Goldwasser, S. Oudard, F. Joly, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II prospective study of gemcitabine and platin-based combination as first-line chemotherapy for metastatic Bellini duct carcinoma patients. Results of GETUG study

S. Culine, B. Duclos, S. Oudard, 2005 .

Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy.

S. Oudard, F. Scotté, A. Fischer, 2009, European urology.

A Prospective International Study on Safety and Efficacy of Hypofractionated Radiation Therapy for Post-Operative Breast Cancer Patients in Asian Countries

M. Calaguas, K. Thephamongkhol, K. Karasawa, 2018, International Journal of Radiation Oncology*Biology*Physics.